Sign in Subscribe
Drug resistance

Genotype-Driven Therapeutics in Epilepsy: Breakthroughs in Treatment Efficacy and Drug Resistance

Strategic Insights

— 2 min read

Research conducted at the International University has shed new light on the complex etiologies of developmental and epileptic encephalopathy (DEE) and metabolic epilepsy (ME) in neonatal intensive care units. By analyzing the genetic abnormalities of 59 patients using exome sequencing, the study identified 40 genetic abnormalities, including de novo variants, that play a crucial role in determining medication efficacy. The research also found that the ketogenic diet showed a positive effect in managing DEE, with over three-quarters of patients improving during a 3-month follow-up.

Key Takeaways:

  • The study analyzed 59 patients with DEE and ME, focusing on genetic analysis using exome sequencing.
  • The research identified 40 genetic abnormalities, including de novo variants, that impact ion channels, glucose transport, transcription regulation, and kinases.
  • Over one-third (34.2%) of patients with DEE had an unfavorable response to anti-seizure medications (ASMs) in the chronic phase.
  • The ketogenic diet showed a positive effect in managing DEE, with over three-quarters (80%) of patients improving during a 3-month follow-up.
  • The medication adverse reaction rate for ME was lower (9.1%) compared to DEE.
  • The study suggests the potential of categorizing drug-resistant variants and the benefits of the ketogenic diet in managing DEE and ME.
  • The research also opens new perspectives on the mechanisms of the ketogenic diet on the discovered genetic variants.
  • Yen Thi My Nguyen, along with other researchers, conducted the study, which was funded by the Vietnam National Foundation For Science And Technology Development.

Statistics:

  • 59 patients with DEE and ME were analyzed in the study.
  • 40 genetic abnormalities were identified using exome sequencing.
  • 34.2% of patients with DEE had an unfavorable response to ASMs.
  • 80% of patients with DEE improved during a 3-month follow-up after the ketogenic diet.
  • 9.1% of patients with ME had an adverse reaction to specialized medications.
  • 5 fatalities were reported among patients with ME.
  • 10 cases with unidentified genetic etiologies were found in the study.

Sources:

  • NewsRx. Studies from International University in the Area of Epilepsy Described (Genotype-driven therapeutics in DEE and metabolic epilepsy: navigating treatment efficacy and drug resistance). Health & Medicine Week. October 11, 2024; p 7308.
  • Nguyen, Y. T. M., Vu, B-Q., Nguyen, D-K., Quach, N-V., Bui, L. T., Hong, J., & Bui, C-B. (2024). Genotype-driven therapeutics in DEE and metabolic epilepsy: navigating treatment efficacy and drug resistance. Scientific Reports, 14(1), 1-13. doi: 10.1038/s41598-024-72683-7

Read more